Although BRAF inhibitors such as vemurafenib can initially induce ferroptosis-like cell death through lipid peroxidation, tumor cells often adapt by upregulating antioxidant defenses, particularly the SLC7A11–GPX4 axis. This evidence concerns the gene GPX4 and neoplasm.